X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31033) 31033
Newspaper Article (1026) 1026
Newsletter (547) 547
Book Chapter (113) 113
Magazine Article (50) 50
Transcript (33) 33
Dissertation (13) 13
Book / eBook (8) 8
Government Document (8) 8
Trade Publication Article (5) 5
Publication (4) 4
Book Review (3) 3
Conference Proceeding (1) 1
Reference (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (20224) 20224
angiogenesis (19429) 19429
animals (13110) 13110
female (10344) 10344
male (10120) 10120
oncology (9105) 9105
cancer (8311) 8311
mice (7441) 7441
vascular endothelial growth factor (6928) 6928
bevacizumab (5785) 5785
endothelial growth-factor (5609) 5609
angiogenesis inhibitors - administration & dosage (5503) 5503
middle aged (5273) 5273
angiogenesis inhibitors - therapeutic use (5091) 5091
aged (4940) 4940
expression (4907) 4907
angiogenesis inhibitors (4511) 4511
tumors (4396) 4396
care and treatment (4311) 4311
metastasis (4193) 4193
apoptosis (4145) 4145
research (4118) 4118
treatment outcome (3807) 3807
ophthalmology (3734) 3734
chemotherapy (3642) 3642
adult (3531) 3531
proteins (3318) 3318
analysis (3227) 3227
vascular endothelial growth factor a - antagonists & inhibitors (3128) 3128
cell line, tumor (3054) 3054
pharmacology & pharmacy (2965) 2965
therapy (2920) 2920
health aspects (2895) 2895
cell biology (2863) 2863
rats (2830) 2830
vegf (2778) 2778
kinases (2717) 2717
neovascularization (2696) 2696
angiogenesis inhibitors - pharmacology (2561) 2561
cancer therapies (2512) 2512
cells (2484) 2484
gene expression (2414) 2414
medicine & public health (2390) 2390
inflammation (2385) 2385
medicine (2370) 2370
rodents (2362) 2362
medicine, research & experimental (2282) 2282
growth (2278) 2278
intravitreal injections (2258) 2258
disease models, animal (2240) 2240
research article (2226) 2226
aged, 80 and over (2181) 2181
studies (2172) 2172
signal transduction (2158) 2158
neovascularization, pathologic - drug therapy (2147) 2147
inhibition (2141) 2141
multidisciplinary sciences (2061) 2061
drug therapy (2041) 2041
antibodies, monoclonal, humanized (2040) 2040
biochemistry & molecular biology (2011) 2011
vascular endothelial growth factor a - metabolism (2009) 2009
physiological aspects (1976) 1976
hypoxia (1970) 1970
cell proliferation - drug effects (1924) 1924
angiogenesis inhibitors - adverse effects (1923) 1923
macular degeneration (1917) 1917
in-vivo (1911) 1911
cell proliferation (1892) 1892
breast cancer (1864) 1864
clinical trials (1863) 1863
antineoplastic combined chemotherapy protocols - therapeutic use (1846) 1846
mice, inbred c57bl (1839) 1839
antineoplastic agents - therapeutic use (1828) 1828
mice, nude (1769) 1769
ranibizumab (1764) 1764
growth factors (1762) 1762
endothelial cells (1759) 1759
surgery (1734) 1734
in-vitro (1720) 1720
endothelium (1715) 1715
activation (1684) 1684
stem cells (1652) 1652
dose-response relationship, drug (1644) 1644
tumor angiogenesis (1634) 1634
retrospective studies (1633) 1633
science (1622) 1622
development and progression (1594) 1594
neoplasms - drug therapy (1574) 1574
medical research (1545) 1545
antibodies, monoclonal - administration & dosage (1535) 1535
immunohistochemistry (1528) 1528
cytokines (1512) 1512
biology (1500) 1500
xenograft model antitumor assays (1495) 1495
time factors (1478) 1478
cells, cultured (1467) 1467
survival (1455) 1455
cell growth (1442) 1442
antineoplastic agents - pharmacology (1427) 1427
review (1396) 1396
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (32365) 32365
German (210) 210
French (154) 154
Japanese (154) 154
Chinese (56) 56
Spanish (53) 53
Portuguese (40) 40
Polish (28) 28
Russian (23) 23
Hungarian (13) 13
Italian (11) 11
Romanian (11) 11
Czech (8) 8
Dutch (6) 6
Swedish (6) 6
Norwegian (5) 5
Korean (4) 4
Turkish (4) 4
Danish (3) 3
Finnish (2) 2
Hebrew (1) 1
Icelandic (1) 1
Lithuanian (1) 1
Persian (1) 1
Serbian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CA: a cancer journal for clinicians, ISSN 0007-9235, 2010, Volume 60, Issue 4, pp. 222 - 243
.... An extensive array of compounds is currently in preclinical development, with many now entering the clinic and/or achieving approval from the US Food and Drug Administration... 
TYROSINE KINASE INHIBITORS | CELL LUNG-CANCER | PHASE-III TRIAL | FARNESYL-PROTEIN TRANSFERASE | FACTOR 1-ALPHA | ONCOLOGY | ENDOTHELIAL-GROWTH-FACTOR | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA | FACTOR EXPRESSION | VASCULAR-PERMEABILITY FACTOR | TUMOR-GROWTH | Neoplasms - metabolism | Nucleic Acid Synthesis Inhibitors - pharmacology | Humans | Receptor Protein-Tyrosine Kinases - physiology | Antibodies, Monoclonal - therapeutic use | Receptors, Notch - antagonists & inhibitors | Protein Binding - drug effects | Angiogenesis Inhibitors - therapeutic use | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Neovascularization, Pathologic - prevention & control | Farnesyltranstransferase - antagonists & inhibitors | Thioredoxins - antagonists & inhibitors | Nucleic Acid Synthesis Inhibitors - therapeutic use | Basic Helix-Loop-Helix Transcription Factors - physiology | Antibodies, Monoclonal - pharmacology | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | Angiogenesis Inhibitors - pharmacology | Receptors, Notch - physiology | Neoplasms - blood supply | Basic Helix-Loop-Helix Transcription Factors - antagonists & inhibitors | Neoplasms - drug therapy | Signal Transduction - drug effects | Cell Transformation, Neoplastic | HSP90 Heat-Shock Proteins - antagonists & inhibitors | Intracellular Signaling Peptides and Proteins - physiology | Complications and side effects | Care and treatment | Ligands (Biochemistry) | Physiological aspects | Development and progression | Dosage and administration | Angiogenesis inhibitors | Neovascularization | Identification and classification | Growth factors | Cancer | Angiogenesis | Pharmacology | FDA approval | Drug therapy | Kinases | Tumors | hypoxia inducible factor (HIF) | kinase inhibitors | growth factors | angiogenesis inhibitors | VEGF | anti-angiogenesis
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 780 - 787
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 2, pp. 172 - 179
Purpose This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma... 
ANGIOGENESIS | ONCOLOGY | PATHWAY | SUNITINIB | ABT-869 | RISK | BRIVANIB | INHIBITOR | CANCER | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Liver Neoplasms - etiology | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Liver Neoplasms - pathology | Carcinoma, Hepatocellular - etiology | Odds Ratio | Drug Administration Schedule | Risk Factors | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Niacinamide - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Phenylurea Compounds - administration & dosage | Protein Kinase Inhibitors - therapeutic use | Sorafenib | Carcinoma, Hepatocellular - pathology | Aged | Indazoles - adverse effects | Indazoles - therapeutic use | Bone3 | ORIGINAL REPORTS | Bios3
Journal Article
Cochrane library, ISSN 1465-1858, 2018, Volume 2018, Issue 1, p. CD009734
Background Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in foetal life. Researchers have recently attempted to use anti‐VEGF... 
Vascular Endothelial Growth Factor A | Eye Disorders | Intravitreal Injections | Laser Therapy | Combined Modality Therapy | Retinal disease | Angiogenesis Inhibitors | Retinopathy of Prematurity | Retinal diseases | Bevacizumab | Randomized Controlled Trials as Topic | Retinal Detachment | Other retinal diseases | Aptamers, Nucleotide | Neonatal care | Ranibizumab | Child health | Eyes & vision | Other neonatal care | Medicine General & Introductory Medical Sciences | Cryotherapy | AVASTIN | EFFICACY | Humans | Infant | Laser Therapy [methods] | DIODE-LASER | Aptamers, Nucleotide [administration & dosage] | MEDICINE, GENERAL & INTERNAL | THERAPY | Angiogenesis Inhibitors [administration & dosage] | INFANTS | Bevacizumab [administration & dosage] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Retinopathy of Prematurity [drug therapy] | AGGRESSIVE POSTERIOR RETINOPATHY | LASER TREATMENT | Retinal Detachment [prevention & control] | Newborn | Cryotherapy [methods] | ZONE-I | INTRAVITREAL BEVACIZUMAB | RANIBIZUMAB | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Aptamers, Nucleotide - administration & dosage | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Aptamers, Nucleotide - adverse effects | Ranibizumab - adverse effects | Angiogenesis Inhibitors - administration & dosage | Retinopathy of Prematurity - drug therapy | Laser Therapy - methods | Ranibizumab - administration & dosage | Cryotherapy - methods | Retinal Detachment - prevention & control | Angiogenesis Inhibitors - adverse effects | Infant, Newborn
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2012, Volume 48, Issue 18, pp. 3319 - 3327
Abstract Background SF1126 is a peptidic pro-drug inhibitor of pan-PI3K/mTORC. A first-in-human study evaluated safety, dose limiting toxicities (DLT... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | PI3K/mTORC pathway | SF1126 | Pharmacokinetics | Refractory solid tumours | B-cell malignancies | ACTIVATION | ANGIOGENESIS | PHOSPHATIDYLINOSITOL 3-KINASE | KINASE | GUIDELINES | CANCER | ONCOLOGY | PI3K PATHWAY | CHRONIC LYMPHOCYTIC-LEUKEMIA | INHIBITOR | ASSOCIATION | Humans | Middle Aged | Male | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Oligopeptides - therapeutic use | Young Adult | Chromones - adverse effects | Aged, 80 and over | Antineoplastic Agents - pharmacokinetics | Chromones - pharmacology | Protein Kinase Inhibitors - pharmacokinetics | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - enzymology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - enzymology | Maximum Tolerated Dose | Oligopeptides - administration & dosage | TOR Serine-Threonine Kinases | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Oligopeptides - pharmacology | Proteins - antagonists & inhibitors | Prodrugs - administration & dosage | Multiprotein Complexes | Salvage Therapy | Chromones - administration & dosage | Molecular Targeted Therapy | Oligopeptides - adverse effects | Mechanistic Target of Rapamycin Complex 1 | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Hypokalemia - chemically induced | Adult | Female | Antineoplastic Agents - pharmacology | Chromones - therapeutic use | Hematologic Diseases - chemically induced | Oligopeptides - pharmacokinetics | Neoplasms - enzymology | Chromones - pharmacokinetics | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Aged | Prodrugs - therapeutic use | Protein Kinase Inhibitors - pharmacology | Infusions, Intravenous | Prodrugs - pharmacology | Gastrointestinal Diseases - chemically induced | Medicine, Experimental | Medical research | Care and treatment | Emergency medical services | Cancer | Index Medicus | PI3K | mTORC pathway
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 18, pp. 2459 - 2465
Purpose This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC).... 
AGENT | AG-013736 | SOLID TUMORS | ANGIOGENESIS | ONCOLOGY | BEVACIZUMAB | POOR RESPONSE | ANTIANGIOGENESIS | EXPRESSION | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Neoplasm Proteins - antagonists & inhibitors | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Breast Neoplasms - therapy | Angiogenesis Inhibitors - administration & dosage | Carcinoma, Ductal, Breast - drug therapy | Hypertension - chemically induced | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Ductal, Breast - pathology | Female | Chemotherapy, Adjuvant | Neutropenia - chemically induced | Angiogenesis Inhibitors - adverse effects | Carcinoma, Ductal, Breast - secondary | Taxoids - adverse effects | Double-Blind Method | Imidazoles - adverse effects | Angiogenesis Inhibitors - pharmacology | Combined Modality Therapy | Imidazoles - pharmacology | Breast Neoplasms - drug therapy | Mucositis - chemically induced | Indazoles - pharmacology | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Thrombophilia - chemically induced | Aged | Protein Kinase Inhibitors - pharmacology | Indazoles - adverse effects | Gastrointestinal Diseases - chemically induced | Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 11/2015, Volume 21, Issue 21, pp. 4801 - 4810
Purpose: This "3+3" phase I study evaluated the safety, biologic, and clinical activity of lenvatinib, an oral multikinase inhibitor, in patients with solid tumors... 
CELL LUNG-CANCER | E7080 | CABOZANTINIB | PHARMACOKINETICS | ANGIOGENESIS | ONCOLOGY | TYROSINE KINASE INHIBITOR | MALIGNANT-MELANOMA | HYPERTENSION | ANTITUMOR ACTIVITIES | ENDOTHELIAL GROWTH-FACTOR | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Quinolines - administration & dosage | Quinolines - pharmacokinetics | Angiogenesis Inhibitors - administration & dosage | Neoplasms - genetics | Antineoplastic Agents - adverse effects | DNA Mutational Analysis | Melanoma - genetics | Phenylurea Compounds - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Phenylurea Compounds - pharmacokinetics | Angiogenesis Inhibitors - adverse effects | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Kaplan-Meier Estimate | Neoplasms - mortality | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Melanoma - pathology | Neoplasms - drug therapy | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Phenylurea Compounds - administration & dosage | Melanoma - drug therapy | Aged | Mutation | Neoplasm Staging | Neoplasms - pathology | Quinolines - adverse effects | Cohort Studies | Melanoma - mortality | RET | lenvatinib | KIT | VEGFR | PDGFR | melanoma | advanced solid tumors | pharmacodynamic | phase I | thyroid cancer | FGFR
Journal Article